The United States Food and Drug Administration has approved a gene therapy that cures a rare form of genetic deafness, a medical breakthrough that scientists say could transform the lives of children born without the ability to hear and open the door to treatments for other forms of inherited hearing loss worldwide.
The therapy, called Otarmeni, was developed by biotechnology company Regeneron and targets otoferlin-related hearing loss, a condition caused by variants in the OTOF gene that affects between 20 and 50 newborns in the United States each year.
The condition occurs when the body fails to produce otoferlin, a critical protein in the inner ear responsible for transmitting sound signals to the brain. Without it, affected children are born profoundly deaf with no viable treatment options beyond hearing aids or cochlear implants, neither of which restores natural hearing.
The approval was granted under the FDA’s new priority voucher programme, marking the introduction of the first gene therapy for genetic hearing loss to ever enter the market. In a move that has drawn widespread attention, Regeneron announced that Otarmeni will be made available completely free of charge to eligible patients in the United States, removing the financial barrier that has historically blocked access to gene therapies, which can cost millions of dollars per treatment.
The approval came on the same day President Donald Trump announced he had completed drug pricing agreements with all 17 of the world’s largest pharmaceutical companies, securing commitments to sell medications to American patients at the lowest prices globally.
Trump described the combined deals as the biggest cut in drug prices in the history of the country, with the Department of Health and Human Services confirming the agreements now cover 86 percent of branded pharmaceuticals. As part of its own deal with the administration, Regeneron committed to investing $27 billion to bring pharmaceutical production back to the United States.
While the condition currently affects a relatively small number of newborns annually, medical experts say the approval carries significance far beyond those numbers. It validates gene therapy as a viable and scalable path to treating inherited hearing conditions and is expected to accelerate research into similar treatments for other forms of genetic deafness that affect far larger populations worldwide.
For families in Nigeria and across Africa, where access to cochlear implants and specialist hearing care remains severely limited, the development represents a significant long term hope for children born with hereditary hearing loss.
